Company Overview and News
In March and April, I wrote a series of articles that examined how far several large-cap service sector stocks might fall during a bear market, and I suggested some alternative investments.
UNP VPU CCL FDX BRK.A SPGI GWW MGA JNJ MG CCL PAYX
A number of recent studies show that companies who focus on the big picture and long-term success tend to better stocks to buy than those that focus exclusively on the here and now.
ABT UL UN UNLYF ULVR NFLX ISRG ABT UNLNF SPGI PX KHC XYL LNSTY
Seasoned dividend investors know that there are big differences between stocks that pay dividends and companies that legitimately have “dividend stocks.” Companies in the latter category have, in many cases, displayed lengthy commitments to not only paying dividends but growing payouts as well.
SPGI PG AFL XOM KO 8686 AFSD CLX MDT
Dan Loeb's 13F portfolio value decreased from $13.86B to $13.32B this quarter. The number of positions decreased from 44 to 40.
PCG ATHTF STZ.B TWX CVS CRM SHW GGAL HON AABA AVGO DOW DOV MELI MAC AET MMM PBF GD TPRE WP KDMN UTX STZ BKI TWC BABA DVMT GOOGL MSFT APY MHK QCOM GRBK MGM FB DOV.WI LEN NXPI PAM PE NFLX PF GOOG BAX LEN.B MPC PAGS ADBE SPGI RSPP VMC MON ICE SWN HON EA WYNN LYB FTI.WI FMC ANTM DWDP BID NEXA BLK XRAY T SUPV DHR ANTX
VANCOUVER, British Columbia, May 18, 2018 (GLOBE NEWSWIRE) -- MGX Minerals Inc. (“MGX” or the “Company”) (CSE:XMG) (FKT:1MG) (OTCQB:MGXMF) is pleased to announce the Company has won the Base and Specialty Metals Industry Leadership Award at the 2018 S&P Global Platts Global Metals Awards, held in London on May 17. Hosted by S&P Global Platts, a leading global energy, metals and commodities information provider, the annual awards program honors exemplary performance in fifteen categories spanning the entire steel, metals and mining complex.
The portfolio continues to be very concentrated with the top five positions accounting for ~30% of the 13F portfolio.
FB SERV AMT.PRB AMT.PRA IBKR CMPR GOOG MHFI SPGI AMT CME AGN SSNC AVGO WSH ICE FIS BIDU CBRE TSM ECL ST EFX A BDX VRSN WLTW ZTS AON V 7018 CBG PRI GOOGL CACC ADI BITA BRCM TNET
In January, I began publishing articles that examined how far several large-cap industrial and service stocks might fall during a bear market, and I suggested some alternative investments.
GD UNP CAT VPU FDX CCL UTX CMI ETN ROST PCP BRK.A NOC SPGI GWW MGA JNJ MG CCL ROK PAYX
Adjusted earnings of $2.00 per share surpassed the Zacks Consensus Estimate by 2 cents and increased 24% on year-over-year basis. The improvement can be attributed to revenue growth, operating leverage and U.S. tax reform that decreased the company’s adjusted effective tax rate to 21.7% from 30.3% in the year-ago quarter.
FISV SPGI VRSK KO UTX IPG
S&P Global Inc. (SPGI - Free Report) ) reported first-quarter 2018 (ended Mar 31, 2018) adjusted earnings per share of $2.00 beating the Zacks Consensus Estimate of $1.98. Earnings increased 24% on a year-over-year basis.
SPGI 7018 CME ADM
(Reuters) - Oil pricing agency S&P Global Platts posted a 3 percent rise in quarterly revenue in its first published results on Thursday, helped by growth in its core subscription business.
The following slide deck was published by S&P Global Inc. in conjunction with their 2018 Q1 earnings call.
3h - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...
as of ET